This medication is given by IV infusion.
Tysabri® is a laboratory-produced monoclonal antibody. It is designed to hamper movement of potentially damaging immune cells from the bloodstream, across the “blood-brain barrier” into the brain and spinal cord.
Tysabri is approved by the U.S. Food and Drug Administration (FDA) as a monotherapy (not to be used in combination with other disease-modifying therapies) for the treatment of relapsing forms of multiple sclerosis, which include clinically isolated syndrome, relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS with relapses).
Click here to read the Tysabri Prescribing Information for healthcare professionals.
Click here to read the Tysabri Medication Guide for patients.
Financial Assistance Program